Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mahmoud A Khaimi. (2018) A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty. Clinical Ophthalmology 12, pages 319-329.
Read now
Read now
Timothy L. Comstock & John D. Sheppard. (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opinion on Pharmacotherapy 19:4, pages 337-353.
Read now
Read now
Timothy L. Comstock & Heleen H. DeCory. (2017) Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. Ocular Immunology and Inflammation 25:2, pages 267-274.
Read now
Read now
Moritz Claudius Daniel, Michael O’Gallagher, Melanie Hingorani, Annegret Dahlmann-Noor & Stephen Tuft. (2016) Challenges in the management of pediatric blepharokeratoconjunctivis / ocular rosacea. Expert Review of Ophthalmology 11:4, pages 299-309.
Read now
Read now
Clifford L Salinger, Michael Gordon, Mitchell A Jackson, Theodore Perl & Eric Donnenfeld. (2015) A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clinical Ophthalmology 9, pages 2089-2097.
Read now
Read now
Martin J Coffey, Heleen H DeCory & Stephen S Lane. (2013) Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clinical Ophthalmology 7, pages 299-312.
Read now
Read now
Articles from other publishers (16)
Xiuwen Zhang, Zhuqing Shen, Hong Sun, Fengjiao Bu & Taomin Huang. (2023) Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis. International Ophthalmology 43:7, pages 2477-2486.
Crossref
Crossref
Yingxin Chen, Xifei Wang, Minghong Gao, Ruiyao Gao & Lixin Song. (2021) The effect of loteprednol suspension eye drops after corneal transplantation. BMC Ophthalmology 21:1.
Crossref
Crossref
Francis S. Mah & Paul M. Karpecki. (2021) Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis. Ophthalmology and Therapy 10:4, pages 859-875.
Crossref
Crossref
Lu Zhao, Ya-jie Sun & Zhi-qiang Pan. (2021) Topical Steroids and Antibiotics for Adult Blepharokeratoconjunctivitis (BKC): A Meta-Analysis of Randomized Clinical Trials. Journal of Ophthalmology 2021, pages 1-9.
Crossref
Crossref
Mohammud G Musleh, Desta Bokre & Annegret H Dahlmann-Noor. (2019) Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. European Journal of Ophthalmology 30:5, pages 856-866.
Crossref
Crossref
Megan E. CavetShellise GlogowskiEzra R. LoweEric Phillips. (2019) Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%. Journal of Ocular Pharmacology and Therapeutics 35:5, pages 291-300.
Crossref
Crossref
Yung Ju YooHee Kyung YangJeong-Min Hwang. (2018) Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children. Journal of Ocular Pharmacology and Therapeutics 34:6, pages 468-476.
Crossref
Crossref
Michael O'Gallagher, Catey Bunce, Melanie Hingorani, Frank Larkin, Stephen Tuft & Annegret Dahlmann-Noor. (2017) Topical treatments for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews 2017:2.
Crossref
Crossref
John D. Sheppard, Timothy L. Comstock & Megan E. Cavet. (2016) Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Advances in Therapy 33:4, pages 532-552.
Crossref
Crossref
Michael O'Gallagher, Catey Bunce, Melanie Hingorani, Frank Larkin, Stephen Tuft & Annegret Dahlmann-Noor. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Katherine Duncan & Bennie H. Jeng. (2015) Medical management of blepharitis. Current Opinion in Ophthalmology 26:4, pages 289-294.
Crossref
Crossref
Onsiri ThanathaneePhornrak SriphonOrapin AnutarapongpanRaweewan AthikulwongsePrakairat ThongphiewRam RangsinOlan Suwan-apichon. (2015) A Randomized Controlled Trial Comparing Dexamethasone with Loteprednol Etabonate on Postoperative Photorefractive Keratectomy. Journal of Ocular Pharmacology and Therapeutics 31:3, pages 165-168.
Crossref
Crossref
Ahmad Kheirkhah, Thomas H. Dohlman, Francisco Amparo, Michael A. Arnoldner, Arsia Jamali, Pedram Hamrah & Reza Dana. (2015) Effects of Corneal Nerve Density on the Response to Treatment in Dry Eye Disease. Ophthalmology 122:4, pages 662-668.
Crossref
Crossref
Stephen C. Pflugfelder, Paul M. Karpecki & Victor L. Perez. (2014) Treatment of Blepharitis: Recent Clinical Trials. The Ocular Surface 12:4, pages 273-284.
Crossref
Crossref
Uwe Pleyer, Paul G. Ursell & Paolo Rama. (2013) Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?. Ophthalmology and Therapy 2:2, pages 55-72.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2013) Loteprednol Etabonate Ophthalmic Gel 0.5 %: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery. Drugs 73:9, pages 949-958.
Crossref
Crossref